期刊文献+

生物标志物对急性心肌梗死介入治疗预后的预测意义 被引量:2

Prognostic Significance of Biomarkers in Predicting Acute Myocardial Infarction after Percutaneous Coronary Intervention
下载PDF
导出
摘要 过去的几十年,在急性心肌梗死的诊断、治疗及预后方面获得了巨大的进步,其中生物标志物在急性心肌梗死患者的术后管理中发挥重要的作用。现综述近十年的报道,聚焦于预后相关生物标志物对急性心肌梗死患者经皮冠状动脉介入术治疗后,短、长期风险评估的研究进展。 In the past few decades, the diagnosis, treatment and prognosis of acute myocardial infarction (AMI) have improved dra- matically. Biomarkers play important roles in the management of AMI patients after treatment. In this review, we focus on advances of prog- nostic biomarkers in the past decade for short- and long-term risk assessment in patients with AMI after percutaneous coronary intervention.
出处 《心血管病学进展》 CAS 2016年第1期37-41,共5页 Advances in Cardiovascular Diseases
基金 上海医学重点专科建设计划(ZK2012A39)
关键词 生物标志物 急性心肌梗死 经皮冠状动脉介入术 预后 Biomarkers Acute myocardial infarction Percutaneous coronary intervention Prognosis
  • 相关文献

参考文献2

二级参考文献27

  • 1Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST- segment elevation myocardial infarction. J Am Coll Cardiol 2000; 36: 970-1062.
  • 2Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, et al. Expression and Regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002; 106: 2961-2966.
  • 3Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, et al. Serum levels of the interleukin- 1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004; 109: 2186-2190.
  • 4Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial Infarction. Circulation 2008; 117: 1936-1944.
  • 5Dhillon OS, Narayan HK, Quinn PA, Squire IB, Davies JE, Ng LL. Interleukin 33 and ST2 in non-ST elevation myocardial infarction: Comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP. Am Heart J 2011; 61:1163-1170.
  • 6Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardio12010; 55: 243-250.
  • 7Eggers KM, Armstrong PW, Califf RM, Simoons ML, Venge P, Wallentin L, et al. ST2 and mortality in non-ST-segment elevation acute coronary syndrome. Am Heart J 2010; 159: 788- 794.
  • 8Granger CB, Goldberg R J, Dabbous O, Pieper KS, Eagle KA, Cannon CP, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2006;163: 2345-2353.
  • 9Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1 like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23:479- 490.
  • 10Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS, et al. Role of ST2 innon-st-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem 2012; 58: 257-266.

共引文献336

同被引文献21

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部